

Consumer Medicine Information

This medicine has **provisional approval** in Australia for some patients with non small cell lung cancer. The decision to approve this medicine has been made on the basis of promising results from preliminary studies. More evidence is required to be submitted when available to fully confirm the benefit and safety of the medicine for this use.

This leaflet provides important information about using LUMAKRAS. **You should also speak to your doctor or pharmacist if you would like further information or if you have any concerns or questions about using LUMAKRAS.**

Where to find information in this leaflet:

1. Why am I using LUMAKRAS?
2. What should I know before I use LUMAKRAS?
3. What if I am taking other medicines?
4. How do I take LUMAKRAS?
5. What should I know while using LUMAKRAS?
6. Are there any side effects?
7. Product details

1. Why am I using LUMAKRAS?

LUMAKRAS contains the active ingredient sotorasib.

It is used to treat a type of lung cancer called non-small cell lung cancer (NSCLC). The cancer is caused by an abnormal protein, called *KRAS G12C* that is involved in the growth of cells.

LUMAKRAS binds to the *KRAS G12C* protein and blocks the function of the protein in tumour cells. This may slow down or stop the growth of your lung cancer.

LUMAKRAS can only be prescribed if you have been previously treated for your lung cancer with other medicines, and your cancer is advanced or has spread to other parts of your body.

If you have any questions about how LUMAKRAS works or why it has been prescribed for you, ask your healthcare provider.